30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Wendy Dixon

Track

Insider profile

Currently holds positions in Incyte Corp, Alkermes Plc, Alkermes Plc and bluebird bio Inc

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Incyte Corp May 21, 2010 -
Independent Director Alkermes Plc Jan. 13, 2011 -
Independent Director Alkermes Plc Sept. 16, 2011 -
Independent Director bluebird bio Inc April 1, 2013 -
Independent Director Voyager Therapeutics Inc Jan. 1, 2017 - June 4, 2020
Independent Chairman of the Board Carisma Therapeutics Inc Dec. 1, 2016 - Feb. 20, 2020
Independent Director Carisma Therapeutics Inc Oct. 22, 2014 - Dec. 1, 2016
Independent Director Orexigen Therapeutics Inc April 20, 2010 - Jan. 8, 2016
Independent Director Ardea Biosciences Inc April 6, 2011 - June 19, 2012
Wendy Dixon's trades of BOW Street Group PLC's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-27 2026-05-22
B Purchase
72,194
454.46
£4,727,055 		72,194 454.46 £4,727,055
2021-06-11 2021-06-10
US Alkermes Plc (ALKS)
PlS Planned sale
90,535 +30.6%
488.18
US$1,630,161 		90,535 +30.6% 488.18 US$1,630,161
2020-08-31 2020-08-27
US Incyte Corp (INCY)
S Sale
5,692 +21.3%
125.89
US$2,417,485 		5,692 +21.3% 125.89 US$2,417,485